Cutaneous WartsPhase 2NCT07307131
Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts
A Phase 2 study testing Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) and Intralesional polidocanol 2% in people with Cutaneous Warts and Human Papilloma Virus (HPV), run by Benha University at 1 site in Egypt.
Trial summary
This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cutaneous Warts, Human Papilloma Virus (HPV)
- What is being tested?
- Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) and Intralesional polidocanol 2%
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2024to 30 Sep 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients over 18 years of age with single or multiple cutaneous warts.
Who cannot join
- History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Head-to-Head Comparison of Intralesional Furosemide-Digoxin Versus Polidocanol for the Treatment of Cutaneous Warts With 6-Month Follow-up
This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.
Read the detailed description
This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.
- Conditions
- Cutaneous Warts, Human Papilloma Virus (HPV)
- Being tested
- Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml), Intralesional polidocanol 2%
- Keywords
- Cutaneous warts, human papillomavirus, intralesional therapy, furosemide, digoxin, polidocanol, sclerotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)Drug
Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)
Intralesional polidocanol 2%Drug
Group B (Active Comparator): Intralesional polidocanol 2%
| Study group | Role | What they receive |
|---|---|---|
| Furosemide and digoxin | Experimental | Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) Receives: Drug: Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) |
| Polidocanol | Active comparator | Intralesional Polidocanol 2% Receives: Drug: Intralesional polidocanol 2% |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete Clinical Response
100% clearance of the treated wart at the end of the treatment period.
Measured: Up to 8 weeks
Secondary outcomes (2)
Incidence and Severity of Adverse Effects
Assessment of side effects such as pain, erythema, edema, and ulceration.
Measured: Throughout the treatment period (up to 8 weeks)
Recurrence Rate
Rate of wart recurrence at the 6-month follow-up visit
Measured: 6 months post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2025
- Study start1 Sep 2024
- Primary completion1 Mar 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cutaneous WartsStudies of the same condition, open and under way.
- More trials run by Benha UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Benha University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ghada Mohamed Shams, Benha University
- Investigators
- Ghada Shams, MD, Principal investigator, Benha University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07307131
- Sponsor's protocol ID
- intralesional treatment warts
- Status last verified
- Dec 2025
- First submitted
- 14 Dec 2025
- Last updated
- 2 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Head-to-Head Comparison of Intralesional Furosemide-Digoxin Versus Polidocanol for the Treatment of Cutaneous Warts With 6-Month Follow-up
- ClinicalTrials.gov ID
- NCT07307131
- Acronym / sponsor ID
- intralesional treatment warts
- Conditions
- Cutaneous Warts, Human Papilloma Virus (HPV)
- Keywords
- Cutaneous warts, human papillomavirus, intralesional therapy, furosemide, digoxin, polidocanol, sclerotherapy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Benha UniversityUniversity, hospital or other
- Study start
- 1 Sep 2024 (actual)
- Primary completion
- 1 Mar 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 29 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.
Detailed description
This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Furosemide and digoxin | Experimental | Drug: Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) |
| Polidocanol | Active comparator | Drug: Intralesional polidocanol 2%Intralesional Polidocanol 2% |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients over 18 years of age with single or multiple cutaneous warts.
Key exclusion criteria (1 listed)
- History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) | Drug | Furosemide and digoxin |
| Intralesional polidocanol 2%Group B (Active Comparator): Intralesional polidocanol 2% | Drug | Polidocanol |
Primary outcome
Complete Clinical Response
Time frame: Up to 8 weeks
100% clearance of the treated wart at the end of the treatment period.
2 secondary outcomes
Incidence and Severity of Adverse Effects
Time frame: Throughout the treatment period (up to 8 weeks)
Recurrence Rate
Time frame: 6 months post-treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Cutaneous Warts
Recruiting
Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts
Warts
RecruitingPhase 4
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
Viral Wart, Plantar Wart
Not yet recruitingEarly Phase 1
the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts.
Warts
Enrolling by invitationEarly Phase 1
Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karachi.
Cutaneous Warts
RecruitingPhase 2/3
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Warts
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ghada Shams, MD principal investigator
Benha University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) and Intralesional polidocanol 2% in people with Cutaneous Warts and Human Papilloma Virus (HPV), run by Benha University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete Clinical Response (time frame: Up to 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026.